98%
921
2 minutes
20
The Omni Legend 32 PET/CT system features silicon photomultiplier (SiPM)-based detectors with bismuth germanium oxide crystals and a 32-cm axial field of view (FOV). The present study aimed to determine the performance characteristics of the Omni Legend 32 PET/CT system according to National Electrical Manufacturers Association (NEMA) NU 2-2018 standards. The PET component of this system comprises 22 detector modules; each module contains 24 detector blocks with 72 bismuth germanium oxide crystals with a volume of 4.1 × 4.1 × 30 mm coupled to 18 SiPM devices with a 6 × 6 mm area, resulting in an axial FOV of 32 cm. The spatial resolution, sensitivity, count rate performance, and image quality delivered by PET were evaluated using the NEMA NU 2-2018 standard. PET images of 2 patients were evaluated to get a visual first impression of the Omni Legend 32 PET/CT system together with Precision DL. The average spatial resolution at 1, 10, and 20 cm from the central axis was 4.3, 5.3, and 6.2 mm, respectively, for filtered backprojection and 3.7, 4.3, and 5.1 mm, respectively, for ordered-subset expectation maximization. The NEMA sensitivity was 47.30 and 47.05 cps/kBq at the axial center of the FOV and at a 10-cm radial offset, respectively. The scatter fraction, count rate accuracy, and peak noise-equivalent count rates were 35.4%, 1.7%, and 501.7 kcps, respectively, at 15.7 kBq/mL. Contrast recovery for the NEMA body phantom from the smallest to the largest sphere ranged from 61.3% to 93.0%, with a background variability of 5.4%-11.7% and a lung error of 5.1% for Q.Clear (β-value, 50). Good patient image quality was obtained with the Omni Legend 32. The Omni Legend 32 has class-leading sensitivity and count rates within the category of whole-body PET systems while maintaining spatial resolution broadly comparable to that of other current SiPM-based PET/CT systems. This combination of properties results in a very good image quality.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2967/jnumed.123.266140 | DOI Listing |
Phys Eng Sci Med
July 2025
Department of Nuclear Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
The Omni Legend (GE Healthcare), equipped with a digital bismuth germanium oxide PET/CT system, has been recently developed. However, the performance of the Omni Legend without a time-of-flight (TOF) system for F-fluciclovine imaging is still unclear. Therefore, this study evaluated the image quality of the Omni Legend according to the Japanese brain tumor phantom test (JBT) criteria, and assessed its potential use for F-fluciclovine imaging.
View Article and Find Full Text PDFEJNMMI Phys
March 2025
Center of Radiology and Diagnostic Imaging, Aizawa Hospital, 2-5-1 Honjo, Matsumoto-Shi, Nagano, 390-8510, Japan.
Background: The digital-BGO PET/CT system, Omni Legend 32, incorporates modified block sequential regularized expectation maximization (BSREM) image reconstruction and a deep learning-based time-of-flight (TOF)-like image quality enhancement process called Precision DL (PDL). The present study aimed to define the fundamental characteristics of PDL using phantom and clinical images.
Methods: A NEMA IEC body phantom was scanned using the Omni Legend 32 PET/CT system.
Phys Med
March 2025
Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, the Netherlands.
Purpose: To assess the lower [F]FDG limit in administered activity and/or scan time reduction capabilities of a digital-BGO 32-cm axial field-of-view PET system while being compliant with current and updated EANM Research Ltd Fluorine-18 accreditation specifications (EARL and EARL).
Methods: EARL and EARL compliance of the digital-BGO system (Omni Legend 32 cm) was tested for several reconstructions, including those that apply precision deep learning-based image enhancement (PDL) as postprocessing, using the calibration QC and NEMA IEC phantom measurements. The image quality QC scan was repeated every hour for 7 h, with each subsequent hour representing a lower administered activity, and reconstructed for various times per bed position, i.
JTO Clin Res Rep
January 2025
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Introduction: Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UTs) are a recently defined group of aggressive cancers in which the effectiveness of standard treatments for lung cancer is unknown.
Methods: We collected clinical, pathologic, and demographic variables from five institutions for patients whose tumors met criteria for SMARCA4-UTs (undifferentiated phenotype and loss of SMARCA4 (BRG1) by immunohistochemistry).
Results: We identified 92 patients with SMARCA4-UTs; 58 (63%) had stage IV disease at diagnosis and 16 (17%) developed recurrent or metastatic disease after initial diagnosis.
Ann Oncol
March 2025
Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA. Electronic address: